BioHealth News Archive
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for…
Read More
The Baltimore Banner: University of Maryland merges engineering and medicine to turn ideas into companies
It’s Baltimore’s latest move toward becoming a tech hub Meredith Cohn - 1/11/2025 - It looks like a rolling suitcase, a mask and some tubes, but for…
Read More
ARPA-H RAPID Program: Rare Disease AI/ML for Precision Integrated Diagnostics
*NOTE: Solution Summary due: February 14, 2025The Big Question What if we could end the rare disease diagnostic odyssey? The Problem Collectively, rare diseases…
Read More
Veralox Therapeutics Expands Its Pipeline with the Exclusive Option to Acquire Nudge Therapeutics
FREDERICK, Md., Jan. 9, 2025 /PRNewswire/ -- Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced today…
Read More
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
GERMANTOWN, Md., & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a…
Read More
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies…
Read More
Montgomery County Economic Development Corporation President and CEO Bill Tompkins Plans to Step Down at the End of His Current Term
Montgomery County, MD — The Montgomery County Economic Development Corporation (MCEDC) announced that Bill Tompkins will step down as President & CEO when his…
Read More
Emmes Group Company, Essex Management Appoints David Loose as Chief Executive Officer
ROCKVILLE, Md., Jan. 7, 2025 /PRNewswire/ -- Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce…
Read More
Why the DMV Region Is Thriving as a Hub for Startups and Innovation
The Washington D.C., Maryland, and Virginia (DMV) region has quickly become one of the nation’s top destinations for startups and tech innovation. With over…
Read More
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax®
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at…
Read More
IonQ Completes Acquisition of Qubitekk, Solidifying Leadership in Quantum Networking
COLLEGE PARK, Md.--(BUSINESS WIRE)-- IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the completion of its acquisition of substantially…
Read More
I-Mab Focuses on Advancing Givastomig as Lead Cancer Therapy in Clinical Development
ROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the…
Read More
MEDTECHDRIVE Q&A: Few medical devices are designed for children. An FDA-Children’s National collaboration aims to change that.
Kolaleh Eskandanian, chief innovation officer at Children’s National Hospital, said the partnership is meant to address the many challenges with developing devices for children…
Read More
Germantown’s Precigen Seeks FDA Approval with Priority Review for New Treatment for Recurrent Respiratory Papillomatosis in Adults
Precigen has submitted a Biologics License Application (BLA) to the FDA, seeking priority review for PRGN-2012, which could become the first FDA-approved treatment for…
Read More
Advancing Biomedical Innovation: ARPA-H’s Transformative 2024 Highlights
BHI is proud to support ARPA-H through its Partnership Intermediary Agreement (PIA), providing EIR commercialization services to advance groundbreaking technologies. Notably, BaySpec, one of…
Read More